Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Allergic Rhinitis - Overview
Allergic Rhinitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Allergic Rhinitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Allergic Rhinitis - Companies Involved in Therapeutics Development
Allergic Rhinitis - Drug Profiles
Allergic Rhinitis - Dormant Projects
Allergic Rhinitis - Discontinued Products
Allergic Rhinitis - Product Development Milestones
Featured News & Press Releases
Jul 22, 2022: Revelation Biosciences announces topline data for phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis
Jul 14, 2022: Revelation Biosciences inc. completes database lock for its phase 1b clear clinical study of REVTx-99b for the treatment of allergic rhinitis
Jun 13, 2022: Revelation Biosciences announces completion of dosing for a phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis
May 23, 2022: Revelation Biosciences announces Safety Monitoring Committee recommendation for continuing evaluation of REVTx-99b for the treatment of allergic rhinitis
Apr 07, 2022: Grand Pharmaceutical Group : Phase III clinical trial of global innovative drug Ryaltris compound sal spray successfully completed the first patient enrollment in Chi
Mar 16, 2022: Wowu Bio: first subject enrolled in the clinical trial after the launch of Artemisia annua pollen allergen sublingual drops
Mar 01, 2022: Miravo Healthcare announces the Cadian commercial launch of Blexten for patients 4 years of age and older
Jan 24, 2022: Zhejiang Wolwo Bio-Pharma announcement on obtaining the summary report of the phase III clinical trial of Artemisia annua Pollen Allergen Sublingual drops for children with rhinitis
Jan 18, 2022: Revelation Biosciences announces first patient enrolled and dosed in phase 1b clinical study of REVTx-99 for the treatment of allergic rhinitis
Jan 14, 2022: Glenmark Specialty S.A. (Switzerland) receives NDA approval by the United States Food and Drug Administration (FDA) for Ryaltris sal spray for the treatment of symptoms of seasol allergic rhinitis in adults and pediatric patients 12 years of age and older
Nov 15, 2021: Revelation Biosciences announces initiation of a phase 1b clinical study of REVTx-99 for the experimental treatment of allergic rhinitis and chronic sal congestion
Oct 20, 2021: The global innovative drug Ryaltris compound sal spray has been granted phase three clinical trial approval
Sep 30, 2021: Glenmark receives marketing approval for Ryaltris, an innovative combition sal spray, in 13 countries across the EU and UK
Jun 23, 2021: sus Pharma announces positive results from a pilot clinical study of FMXIN002 intrasal powder epinephrine spray in patients with Seasol Allergic Rhinitis
Jun 08, 2021: Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Allergic Rhinitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Allergic Rhinitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Allergic Rhinitis - Pipeline by Advagene Biopharma Co Ltd, 2022
Allergic Rhinitis - Pipeline by ALK-Abello AS, 2022
Allergic Rhinitis - Pipeline by Alkem Laboratories Ltd, 2022
Allergic Rhinitis - Pipeline by Allovate LLC, 2022
Allergic Rhinitis - Pipeline by AOBiome LLC, 2022
Allergic Rhinitis - Pipeline by ASIT Biotech SA, 2022
Allergic Rhinitis - Pipeline by AtoGen Co Ltd, 2022
Allergic Rhinitis - Pipeline by Bai Shuo Beijing Pharmaceutical Technology Co Ltd, 2022
Allergic Rhinitis - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, 2022
Allergic Rhinitis - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Allergic Rhinitis - Pipeline by Dobecure SL, 2022
Allergic Rhinitis - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Allergic Rhinitis - Pipeline by Emergo Therapeutics Inc, 2022
Allergic Rhinitis - Pipeline by EmphyCorp Inc, 2022
Allergic Rhinitis - Pipeline by Eurofarma Laboratorios SA, 2022
Allergic Rhinitis - Pipeline by Faes Farma SA, 2022
Allergic Rhinitis - Pipeline by FunPep Co Ltd, 2022
Allergic Rhinitis - Pipeline by Genu Pharma Co Ltd, 2022
Allergic Rhinitis - Pipeline by GL Pharm Tech Corp, 2022
Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, 2022
Allergic Rhinitis - Pipeline by HAL Allergy BV, 2022
Allergic Rhinitis - Pipeline by Inimmune Corp, 2022
Allergic Rhinitis - Pipeline by Inmunotek SL, 2022
Allergic Rhinitis - Pipeline by Liminal BioSciences Inc, 2022
Allergic Rhinitis - Pipeline by Link Health Group, 2022
Allergic Rhinitis - Pipeline by Marinomed Biotech AG, 2022
Allergic Rhinitis - Pipeline by MD Healthcare Inc, 2022
Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Allergic Rhinitis - Pipeline by Nasus Pharma Ltd, 2022
Allergic Rhinitis - Pipeline by Navipharm Co Ltd, 2022
Allergic Rhinitis - Pipeline by NeuCen BioMed Co Ltd, 2022
Allergic Rhinitis - Pipeline by Oneness Biotech Co Ltd, 2022
Allergic Rhinitis - Pipeline by Palo Alto pharmaceuticals Inc, 2022
Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
Allergic Rhinitis - Pipeline by PharmaKing Co Ltd, 2022
Allergic Rhinitis - Pipeline by Raphas Co Ltd, 2022
Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Allergic Rhinitis - Pipeline by Revelation Biosciences Inc, 2022
Allergic Rhinitis - Pipeline by Revolo Biotherapeutics Ltd, 2022
Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, 2022
Allergic Rhinitis - Pipeline by Sama Pharm Co Ltd, 2022
Allergic Rhinitis - Pipeline by Sedor Pharmaceuticals LLC, 2022
Allergic Rhinitis - Pipeline by Shouyao Holding Co Ltd, 2022
Allergic Rhinitis - Pipeline by Siolta Therapeutics Inc, 2022
Allergic Rhinitis - Pipeline by Stallergenes Greer Ltd, 2022
Allergic Rhinitis - Pipeline by Synokem Pharmaceuticals Ltd, 2022
Allergic Rhinitis - Pipeline by The Geneva Biotech Center SA, 2022
Allergic Rhinitis - Pipeline by United Biomedical Inc, 2022
Allergic Rhinitis - Pipeline by Vactech Oy, 2022
Allergic Rhinitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2022
Allergic Rhinitis - Pipeline by Yuyu Pharma Inc, 2022
Allergic Rhinitis - Pipeline by Zhejiang Wolwo Bio-Pharmaceutical Co Ltd, 2022
Allergic Rhinitis - Pipeline by Zydus Lifesciences Ltd, 2022
Allergic Rhinitis - Dormant Projects, 2022
Allergic Rhinitis - Discontinued Products, 2022
Allergic Rhinitis - Discontinued Products, 2022 (Contd..1)